Patents by Inventor Xavier De Lamballerie

Xavier De Lamballerie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DHODH INHIBITORS AND THEIR USE AS ANTIVIRAL AGENTS
    Publication number: 20220227720
    Abstract: The present invention relates to a compound, or a dimer or a pharmaceutically acceptable salt or solvate of said compound or dimer, for use in a method for the treatment of a disease, disorder or condition caused by an RNA virus, said compound having the general structure shown in Formula (I).
    Type: Application
    Filed: May 6, 2020
    Publication date: July 21, 2022
    Inventors: Chris Meier, Matthias Winkler, Katharina Pfaff, Nora Constanze Fohrmann, Gilles Querat, Xavier de Lamballerie
  • METHOD FOR RAPID GENERATION OF AN ATTENUATED RNA VIRUS
    Publication number: 20200270584
    Abstract: The present invention harnesses the power of mutagenesis to produce an attenuated RNA virus in a very short period, i.e. as soon as the complete sequence of the target virus is known and an infectious genome can be produced.
    Type: Application
    Filed: March 9, 2020
    Publication date: August 27, 2020
    Inventors: Antoine Nougairéde, Lauriane De Fabritus, Fabien Aubry, Xavier De Lamballerie, Ernest Andrew Gould
  • Method for rapid generation of an attenuated RNA virus
    Patent number: 10619137
    Abstract: The present invention harnesses the power of mutagenesis to produce an attenuated RNA virus in a very short period, i.e. as soon as the complete sequence of the target virus is known and an infectious genome can be produced.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: April 14, 2020
    Assignees: UNIVERSITÉ D'AIX-MARSEILLE, INSERM
    Inventors: Antoine Nougairéde, Lauriane De Fabritus, Fabien Aubry, Xavier De Lamballerie, Ernest Andrew Gould
  • Method for rapid generation of an infectious RNA virus
    Patent number: 10407667
    Abstract: The present invention relates to a method for rapid generation of an infectious RNA virus that completely eliminates the need of constructing a full-length c DNA, which covers the entire viral genome, cloning and propagating such full length c DNA.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: September 10, 2019
    Assignees: UNIVERSITÉ D'AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Fabien Aubry, Antoine Nougairéde, Gilles Quérat, Xavier De Lamballerie, Ernest Andrew Gould, Lauriane De Fabritus
  • Methods and pharmaceutical compositions for the treatment of ebola virus disease
    Patent number: 10098879
    Abstract: The invention relates to methods and pharmaceutical compositions for the treatment of Ebola Virus Disease. In particular the present relates to a method of treating Ebola Virus Disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of Favipiravir.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: October 16, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE BORDEAUX, CHU DE BORDEAUX, TOYAMA CHEMICAL CO., LTD
    Inventors: Denis Malvy, Sylvain Baize, Xavier De Lamballerie, Hervé Raoul, Cédric Laouenan, Jeremie Guedj, France Mentre
  • METHOD FOR RAPID GENERATION OF AN INFECTIOUS RNA VIRUS
    Publication number: 20180208907
    Abstract: The present invention relates to a method for rapid generation of an infectious RNA virus that completely eliminates the need of constructing a full-length c DNA, which covers the entire viral genome, cloning and propagating such full length c DNA.
    Type: Application
    Filed: June 19, 2015
    Publication date: July 26, 2018
    Inventors: Fabien Aubry, Antoine Nougairéde, Gilles Quérat, Xavier De Lamballerie, Ernest Andrew Gould, Lauriane De Fabritus
  • METHOD FOR RAPID GENERATION OF AN ATTENUATED RNA VIRUS
    Publication number: 20180201908
    Abstract: The present invention harnesses the power of mutagenesis to produce an attenuated RNA virus in a very short period, i.e. as soon as the complete sequence of the target virus is known and an infectious genome can be produced.
    Type: Application
    Filed: June 19, 2015
    Publication date: July 19, 2018
    Inventors: Antoine Nougairéde, Lauriane De Fabritus, Fabien Aubry, Xavier De Lamballerie, Ernest Andrew Gould
  • Avermectins and milbemycins for the treatment, prevention or amelioration of flavivirus infections
    Patent number: 8741856
    Abstract: Avermectin and milbemycin compounds, particularly the substance ivermectin, for preparing an antiviral medicament for the treatment, prevention or amelioration of a Flavivirus infection, such as those caused by YFV (yellow fever virus), DENV (Dengue virus), JEV (Japanese encephalitis virus), TBEV (tick-borne encephalitis virus) or MODV (Modoc virus) are provided. The antiviral compositions of the present invention are suitable for oral administration to a Flavivirus-infected subject or a subject at risk of a infection, such as a human or other mammal.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: June 3, 2014
    Assignees: Consiglio Nazionale Delle Ricerche, Aix-Marseille Universite', Katholieke Universiteit Leuven-K.U. Leuven R&D
    Inventors: Mario Milani De Mayo De Mari, Eloise Mastrangelo, Martino Bolognesi, Xavier De Lamballerie, Boris Pastorino, Johan Neyts, Suzanne Kaptein
  • AVERMECTINS AND MILBEMYCINS FOR THE TREATMENT, PREVENTION OR AMELIORATION OF FLAVIVIRUS INFECTIONS
    Publication number: 20120208778
    Abstract: Avermectin and milbemycin compounds, particularly the substance ivermectin, for preparing an antiviral medicament for the treatment, prevention or amelioration of a Flavivirus infection, such as those caused by YFV (yellow fever virus), DENV (Dengue virus), JEV (Japanese encephalitis virus), TBEV (tick-borne encephalitis virus) or MODV (Modoc virus) are provided. The antiviral compositions of the present invention are suitable for oral administration to a Flavivirus-infected subject or a subject at risk of a Flavivirus infection, such as a human or other mammal.
    Type: Application
    Filed: October 21, 2010
    Publication date: August 16, 2012
    Applicants: Consiglio Nazionale Delle Richerche, Katholieke Universiteit Leuven - K.U. Leuven R&D, Aix-Marseille Universite
    Inventors: Mario Milani De Mayo De Mari, Eloise Mastrangelo, Martino Bolognesi, Xavier De Lamballerie, Boris Pastorino, Johan Neyts, Suzanne Kaptein